Avista Corp. (AVA) Misses Q2 EPS by 13c; offers guidance
Tweet
Share
E-mail
Get Alerts AVA Hot Sheet
Price: $38.53 --0%
Financial Fact:
Depreciation and amortization: 40.24M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Depreciation and amortization: 40.24M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Avista Corp. (NYSE: AVA) reported Q2 EPS of $0.17, $0.13 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $400 million versus the consensus estimate of $411.41 million.
GUIDANCE:
Avista Corp. sees FY2025 EPS of $2.52-$2.72, versus the consensus of $2.54.
For earnings history and earnings-related data on Avista Corp. (AVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Pyxis Oncology, Inc. (PYXS) Misses Q2 EPS by 4c
- Zenas BioPharma, Inc. (ZBIO) Reports Q2 Loss of $1.77
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
